Clinical Oncology

[Individualized treatment of advanced/metastatic adult soft tissue sarcomas]

SZŰCS Zoltan1, JONES L. Robin

DECEMBER 10, 2016

Clinical Oncology - 2016;3(04)

[Considering the extreme histological heterogeneity of soft tissue sarcomas (STS), their management is an art of its own. Over the last decade the treatment of STSs has been slowly shifting towards a more individualized, histology driven tailored approach. With the availability of novel antineoplastic agents and the differential sensitivity of different subtypes of sarcomas to these drugs, we aim to provide some guidance in terms of optimal sequencing of therapies. Furthermore, we discuss some of the emerging targeted therapies currently evaluated for the palliative treatment of the more common and some of the very rare STS subtypes.]

AFFILIATIONS

  1. The Ipswich Hospital NHS Trust, Ipswich

COMMENTS

0 comments

Further articles in this publication

Clinical Oncology

[Foreword]

A szerkesztők

Clinical Oncology

[Reminiscences of a Peer – Remembering Sándor Eckhardt]

KERPEL-FRONIUS Sándor

Clinical Oncology

[News from the World]

Clinical Oncology

[Side-effects of immunotherapy]

LANDHERR László

[The immune system has an important role in controlling and eradicating cancer cells. Antibody therapy against several negative immunologic regulators (checkpoints) has demonstrated promise in a variety of malignancies. The immune checkpoint blockade with antibodies against cytotoxic T lymphocyte- associated antigen 4 (CTLA-4) and the programmed cell death protein 1 pathway (PD-1/PD-L1) and its ligand have a unique and distinct pattern of adverse events. Immune-related adverse events are most commonly observed in the skin, gastrointestinal tract, liver and the endocrine system. Early recognition and treatment are believed to be important in mitigating severity of such adverse effects.]

Clinical Oncology

[Chemotherapy of multiple myeloma]

MIKALA Gábor, CEGLÉDI Andrea, CSACSOVSZKI Ottó, SZEMLAKY Zsuzsanna, PETŐ Mónika

[Multiple myeloma is a multifaceted haematological disease, a plasma cell malignancy that may pose an oncological differential diagnostic challenge. The importance of this disease is emphasized by its incidence. Since there are multiple novel therapies available for myeloma patients, decade-long survival in not uncommon; therefore, myeloma patients provide a signifi cant part of the patients referred to hematological clinics. In this review, fi rst the novel diagnostic criteria are introduced, followed by the standard therapeutic approaches for transplant-eligible and ineligible patients. As the disease nearly always relapses, the later line therapies available in this malignancy are presented with a special emphasis on the Hungarian haematological practice.]

All articles in the issue

Related contents

Clinical Oncology

[Recent strategies in the chemoterapy of soft tissue tumors]

PÁPAI Zsuzsanna, KISS Nóra

[Conventional adjuvant therapy is, in most cases, either the well-known standard doxorubicin monotherapy or the combination of doxorubicin + ifosfamide. No clear guideline has been developed yet - adjuvant therapy is recommended in cases with high grade, larger than 10 cm, sarcoma, where surgery hasn’t been suffi ciently radical, and adjuvant radiotherapy may not be advisable. In locally advanced tumors, due to the requirements of limb salvage, isolated limb perfusion is recommended. As a new compound, hafnium-oxide nanoparticles (NBTXR3) can be useful in local therapy: combining intratumoral injection and radiotherapy may be a fl agship initiative, however further investigations are necessary. In the treatment of metastatic tumors, beside the standard methods, new, targeted treatments are becoming more and more prevalent: in leiomyosarcomas trabectedine, pazopanib and olaratumab; in liposarcomas trabectedine and eribulin; in synovial sarcomas pazopanib; and in imatinib-resistant GIST, sunitinib and regorafenib. Soft tissue sarcomas are rare tumors categorized as heterogeneous histological subtypes. In their treatment, it is key to customize the treatment based on these subtypes and interdisciplinary collaboration with the orthopedic surgeon, the pathologist and the radiotherapist to determine the suitable therapy for each individual.]

Clinical Neuroscience

Alexithymia is associated with cognitive impairment in patients with Parkinson’s disease

SENGUL Yildizhan, KOCAK Müge, CORAKCI Zeynep, SENGUL Serdar Hakan, USTUN Ismet

Cognitive dysfunction (CD) is a common non-motor symptom of Parkinson’s disease (PD). Alexithy­mia is a still poorly understood neuropsychiatric feature of PD. Cognitive impairment (especially visuospatial dysfunction and executive dysfunction) and alexithymia share com­mon pathology of neuroanatomical structures. We hypo­thesized that there must be a correlation between CD and alexithymia levels considering this relationship of neuroanatomy. Objective – The aim of this study was to evaluate the association between alexithymia and neurocognitive function in patients with PD. Thirty-five patients with PD were included in this study. The Toronto Alexithymia Scale–20 (TAS-20), Geriatric Depression Inventory (GDI) and a detailed neuropsychological evaluation were performed. Higher TAS-20 scores were negatively correlated with Wechsler Adult Intelligence Scale (WAIS) similarities test score (r =-0.71, p value 0.02), clock drawing test (CDT) scores (r=-0.72, p=0.02) and verbal fluency (VF) (r=-0.77, p<0.01). Difficulty identifying feelings subscale score was negatively correlated with CDT scores (r=-0.74, p=0.02), VF scores (r=-0.66, p=0.04), visual memory immediate recall (r=-0.74, p=0.01). VF scores were also correlated with difficulty describing feelings (DDF) scores (r=-0.66, p=0.04). There was a reverse relationship bet­ween WAIS similarities and DDF scores (r=-0.70, p=0.02), and externally oriented-thinking (r=-0.77,p<0.01). Executive function Z score was correlated with the mean TAS-20 score (r=-62, p=0.03) and DDF subscale score (r=-0.70, p=0.01) Alexithymia was found to be associated with poorer performance on visuospatial and executive function test results. We also found that alexithymia was significantly correlated with depressive symptoms. Presence of alexithymia should therefore warn the clinicians for co-existing CD.

Clinical Neuroscience

Evaluation of the effectiveness of transforaminal epidural steroid injection in far lateral lumbar disc herniations

EVRAN Sevket, KATAR Salim

Far lateral lumbar disc herniations (FLDH) consist approximately 0.7-12% of all lumbar disc herniations. Compared to the more common central and paramedian lumbar disc herniations, they cause more severe and persistent radicular pain due to direct compression of the nerve root and dorsal root ganglion. In patients who do not respond to conservative treatments such as medical treatment and physical therapy, and have not developed neurological deficits, it is difficult to decide on surgical treatment because of the nerve root damage and spinal instability risk due to disruption of facet joint integrity. In this study, we aimed to evaluate the effect of transforaminal epidural steroid injection (TFESI) on the improvement of both pain control and functional capacity in patients with FLDH. A total of 37 patients who had radicular pain caused by far lateral disc herniation which is visible in their lumbar magnetic resonance imaging (MRI) scan, had no neurological deficit and did not respond to conservative treatment, were included the study. TFESI was applied to patients by preganglionic approach. Pre-treatment Visual Analogue Scale (VAS) and Oswestry Disability Index (ODI) scores of the patients were compared with the 3rd week, 3rd month and 6th month scores after the procedure. The mean initial VAS score was 8.63 ± 0.55, while it was 3.84 ± 1.66, 5.09 ± 0.85, 4.56 ± 1.66 at the 3rd week, 3rd month and 6th month controls, respectively. This decrease in the VAS score was found statistically significant (p = 0.001). ODI score with baseline mean value of 52.38 ± 6.84 was found to be 18.56 ± 4.95 at the 3rd week, 37.41 ± 14.1 at the 3rd month and 34.88 ± 14.33 at the 6th month. This downtrend of pa­tient’s ODI scores was found statistically significant (p = 0.001). This study has demonstrated that TFESI is an effective method for gaining increased functional capacity and pain control in the treatment of patients who are not suitable for surgical treatment with radicular complaints due to far lateral lumbar disc hernia.

Hypertension and nephrology

[About the care of patients with hyperuricaemia and gout]

[This consensus document is intended to provide guidance for the effective and efficient treatment of asymptomatic individuals with high uric acid levels and gout patients.]